Alexion Partnering Day
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and ultra-rare diseases. Our passion is to deliver life-transforming therapies to patients who suffer the severe morbidities and high mortality associated with ultra-rare diseases and who often have no other treatment options.
Our 2007 launch of Soliris¬Æ (eculizumab) in paroxysmal nocturnal hemoglobinuria (PNH) is widely considered the most successful introduction of an ultra-orphan drug by any company. Soliris was the first drug ever approved under both Priority Review in the US and Accelerated Assessment in the EU, and has since won the prestigious Prix Galien awards in the US and France. Today, Soliris is approved in PNH in more than 40 countries and in atypical hemolytic uremic syndrome (aHUS), a second severe, ultra-rare and life-threatening disorder, in 30. More than 1,100 Alexion employees now work in 23 company facilities in North America, Europe, Asia-Pacific and Latin America to support ongoing drug development and commercialization.
Why Partner with Alexion?
Through our passion to deliver life-transforming therapies for patients with devastating and ultra-rare diseases, Alexion has become an acknowledged global leader in the diverse skills needed to move highly innovative therapies rapidly and effectively from the laboratory to patients in need. Increasingly, we seek to work with organizations in academia and industry who share our commitment to individuals suffering with disorders of extreme severity and rarity.
Our ongoing success with Soliris — and our rapid progress in our other development programs — is based in a narrow focus on overcoming the steep hurdles inherent in the field of ultra-orphan therapies. Through this focus, we have built our skills in breakthrough innovation in little-studied fields‚Ä¶ design and recruitment of first-ever clinical studies in sparse patient populations‚Ä¶ working with healthcare authorities in disorders that lack regulatory precedents‚Ä¶ educating practitioners about rarely-seen diseases‚Ä¶ and maximizing patient access to high-value therapeutics.
Our depth in each of these areas makes us a desirable partner for organizations that seek to collaborate at any step in the process. Importantly, we seek to pursue a relatively small range of programs at any one time. There is no “second tier” pipeline at Alexion: any program we undertake is of central importance to our management and employees, and is driven with the full range of resources at our disposal.
Confirmed Alexion Participants
Vice President, Corporate Strategy and Business Development
Executive Director, Business Development
|What:||Alexion Partnering Day|
|When:||Tuesday, July 17, 2012
8:30AM – 6:00PM
400 Oyster Point Blvd. Suite 221
South San Francisco, CA 94080
|Attire:||Business attire suggested|